Seek Returns logo

Command Palette

Search for a command to run...

NVSEF vs. RHHVF: A Head-to-Head Stock Comparison

Here's a clear look at NVSEF and RHHVF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolNVSEFRHHVF
Company NameNovartis AGRoche Holding AG
CountrySwitzerlandSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization299.05 billion USD313.72 billion USD
CurrencyUSDUSD
ExchangeOTC Markets OTCPKOTC Markets OTCQX
Listing DateApril 26, 2010February 13, 2009
Security TypeCommon StockCommon Stock

NVSEF's market capitalization stands at 299.05 billion USD, while RHHVF's is 313.72 billion USD, indicating their market valuations are broadly comparable.

Historical Performance

This chart compares the performance of NVSEF and RHHVF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVSEF vs. RHHVF: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolNVSEFRHHVF
5-Day Price Return2.60%3.86%
13-Week Price Return9.79%--
26-Week Price Return21.86%--
52-Week Price Return21.72%--
Month-to-Date Return-8.71%-1.23%
Year-to-Date Return8.70%-1.23%
10-Day Avg. Volume3.81M0.88M
3-Month Avg. Volume3.34M0.88M
3-Month Volatility19.13%--
Beta1.051.46

With betas of 1.05 for NVSEF and 1.46 for RHHVF, both stocks show similar sensitivity to overall market movements.

Profitability

Return on Equity (TTM)

NVSEF

32.75%

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

In the upper quartile for the Pharmaceuticals industry, NVSEF's Return on Equity of 32.75% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

Return on Equity data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

NVSEF

24.83%

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

A Net Profit Margin of 24.83% places NVSEF in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

Net Profit Margin data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

NVSEF

31.00%

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

An Operating Profit Margin of 31.00% places NVSEF in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RHHVF

--

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

Operating Profit Margin data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolNVSEFRHHVF
Return on Equity (TTM)32.75%--
Return on Assets (TTM)13.24%--
Net Profit Margin (TTM)24.83%--
Operating Profit Margin (TTM)31.00%--
Gross Profit Margin (TTM)75.82%--

Financial Strength

Current Ratio (MRQ)

NVSEF

1.12

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

NVSEF's Current Ratio of 1.12 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RHHVF

--

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

Current Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

NVSEF

0.77

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

NVSEF's leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.77. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RHHVF

--

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

Debt-to-Equity Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

NVSEF

15.76

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

NVSEF's Interest Coverage Ratio of 15.76 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RHHVF

--

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

Interest Coverage Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolNVSEFRHHVF
Current Ratio (MRQ)1.12--
Quick Ratio (MRQ)0.89--
Debt-to-Equity Ratio (MRQ)0.77--
Interest Coverage Ratio (TTM)15.76--

Growth

Revenue Growth

NVSEF vs. RHHVF: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolNVSEFRHHVF
Revenue Growth (MRQ vs Prior YoY)2.23%--
Revenue Growth (TTM vs Prior YoY)8.91%--
3-Year Revenue CAGR9.10%--
5-Year Revenue CAGR2.45%--

EPS Growth

NVSEF vs. RHHVF: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolNVSEFRHHVF
EPS Growth (MRQ vs Prior YoY)-11.02%--
EPS Growth (TTM vs Prior YoY)21.92%--
3-Year EPS CAGR31.22%--
5-Year EPS CAGR15.26%--

Dividend

Dividend Yield (TTM)

NVSEF

2.86%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

NVSEF's Dividend Yield of 2.86% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RHHVF

0.00%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

RHHVF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NVSEF vs. RHHVF: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

NVSEF

102.24%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

NVSEF's Dividend Payout Ratio of 102.24% is above 100%. This means the company is paying out more in dividends than it earned, a practice that is often unsustainable and could indicate a risk to future dividend stability.

RHHVF

0.00%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

RHHVF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NVSEF vs. RHHVF: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolNVSEFRHHVF
Dividend Yield (TTM)2.86%0.00%
Dividend Payout Ratio (TTM)102.24%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

NVSEF

19.53

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

NVSEF's P/E Ratio of 19.53 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RHHVF

--

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

P/E Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

NVSEF

4.85

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

NVSEF's P/S Ratio of 4.85 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RHHVF

--

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

P/S Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

NVSEF

5.66

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

NVSEF's P/B Ratio of 5.66 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company's net assets, a valuation that hinges on its ability to generate superior profits.

RHHVF

--

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

P/B Ratio data for RHHVF is currently unavailable.

NVSEF vs. RHHVF: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolNVSEFRHHVF
Price-to-Earnings Ratio (TTM)19.53--
Price-to-Sales Ratio (TTM)4.85--
Price-to-Book Ratio (MRQ)5.66--
Price-to-Free Cash Flow Ratio (TTM)17.91--